We work on drug discovery by combining our proprietary global top level antibody engineering and cyclic peptide technology and biological hypothesis of disease causing mechanism to solve the unmet medical needs.

Cyclic Peptide

Intracellular Protein-Protein Interactions (PPIs) are tough target for both small molecule and antibody drug. Although peptide therapeutics is thought to be an ideal PPI modulator, conventional peptides are neither orally available nor cell-permeable. With advanced fusion of biotechnology and chemistry, we have successfully established proprietary orally available and cell-permeable cyclic peptide library and its screening technology. We are planning to have our first cyclic peptide drug to enter into clinical study by end of 2021, and we have multiple cyclic peptide projects in the drug discovery stage.

< Back